by The Europe IV hydration therapy market has been witnessing high demand over the past few years owing to rising geriatric population suffering from various age-related ailments requiring IV therapy. IV hydration therapy involves administering saline solutions, minerals, glucose directly into the bloodstream intravenously to effectively treat dehydration and electrolyte imbalances. It is gaining acceptance as an effective preventive healthcare solution when taken before or after consuming alcohol, during flu/cold recovery, hangovers, jet lag or sports injuries. The Europe IV hydration therapy market caters to a wide range of products including solutions, devices, disposables and equipment. With increasing awareness about preventive healthcare measures, Europe IV hydration therapy market is estimated to be valued at US$ 301.46 Mn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Europe IV hydration therapy market size are Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina, Phoenix Pharmaceuticals, Abcam plc. They are focusing on innovation initiatives and strategic partnerships to strengthen their market position.
Key opportunities in the market include rising demand for home-based IV therapy due to Covid pandemic, increasing R&D for treatment of chronic diseases requiring IV therapy and growing adoption of ambulatory IV therapy for medical tourism. Technological advancements such as computer-controlled volumetric infusion pumps, improved catheter and cannula designs are also contributing to market growth.
Market drivers
The increasing geriatric population in European countries prone to age-related ailments requiring IV rehydration and nutrition support is a major growth driver for Europe IV hydration therapy market. As per WHO, around 25% of European population is estimated to be aged 60 years or older by 2050. Additionally, growing prevalence of chronic diseases like cancer requiring IV medication and busy lifestyles leading to increased instances of dehydration also contribute to market growth.
Current Challenges in Europe IV Hydration Therapy Market
The Europe IV hydration therapy market faces various challenges currently. There is a lack of awareness about the benefits of IV hydration therapy and dehydration in general among people. This results in low adoption rates. There are also issues related to cost and pricing of the treatment. It is still considered a costly treatment option by many. Further, the dominance of oral rehydration therapies continues to hinder the market growth of IV hydration therapy to some extent.
SWOT Analysis
Strength: The treatment is effective for rehydrating patients suffering from dehydration in a very short span of time. IV therapy ensures fluids reach directly into the bloodstream for quick absorption and effect.
Weakness: High costs associated with IV treatments and equipment. Additional medical staff required during the treatment.
Opportunity: Growing geriatric population prone to dehydration offers potential for growth. Increasing incidence of lifestyle diseasesresulting in dehydration presents opportunities.
Threats: Competition and domination from conventional oral rehydration therapies. Stringent regulations pertaining to IV therapies.
The UK and Germany account for the major share of the Europe IV hydration therapy market in terms of value currently due to higher adoption and awareness levels. These countries are also hubs for key market players operating in the region. Germany is expected to witness the fastest growth over the forecast period supported by rising healthcare expenditure and a robust healthcare system.
Russia is also emerging as a high potential growth market for IV hydration therapy in Europe attributed to increasing incidences of lifestyle diseases, development of healthcare infrastructure and adoption of advanced treatment options.
